University of Dundee, Dundee, UK
Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Eur Respir Rev. 2024 Sep 4;33(173). doi: 10.1183/16000617.0049-2024. Print 2024 Jul.
The overall burden of bronchiectasis on patients and healthcare systems has not been comprehensively described. Here, we present the findings of a systematic literature review that assessed the clinical and socioeconomic burden of bronchiectasis with subanalyses by aetiology (PROSPERO registration: CRD42023404162).
Embase, MEDLINE and the Cochrane Library were searched for publications relating to bronchiectasis disease burden (December 2017-December 2022). Journal articles and congress abstracts reporting on observational studies, randomised controlled trials and registry studies were included. Editorials, narrative reviews and systematic literature reviews were included to identify primary studies. PRISMA guidelines were followed.
1585 unique publications were identified, of which 587 full texts were screened and 149 were included. A further 189 citations were included from reference lists of editorials and reviews, resulting in 338 total publications. Commonly reported symptoms and complications included dyspnoea, cough, wheezing, sputum production, haemoptysis and exacerbations. Disease severity across several indices and increased mortality compared with the general population was reported. Bronchiectasis impacted quality of life across several patient-reported outcomes, with patients experiencing fatigue, anxiety and depression. Healthcare resource utilisation was considerable and substantial medical costs related to hospitalisations, treatments and emergency department and outpatient visits were accrued. Indirect costs included sick pay and lost income.
Bronchiectasis causes significant clinical and socioeconomic burden. Disease-modifying therapies that reduce symptoms, improve quality of life and reduce both healthcare resource utilisation and overall costs are needed. Further systematic analyses of specific aetiologies and paediatric disease may provide more insight into unmet therapeutic needs.
支气管扩张症给患者和医疗系统带来的整体负担尚未得到全面描述。在这里,我们呈现了一项系统文献综述的结果,该综述评估了支气管扩张症的临床和社会经济负担,并按病因进行了亚分析(PROSPERO 注册:CRD42023404162)。
检索了 Embase、MEDLINE 和 Cochrane 图书馆中与支气管扩张症疾病负担相关的出版物(2017 年 12 月至 2022 年 12 月)。纳入了报告观察性研究、随机对照试验和登记研究的期刊文章和会议摘要。纳入社论、叙述性综述和系统文献综述以确定原始研究。遵循 PRISMA 指南。
共确定了 1585 篇独特的出版物,其中 587 篇全文进行了筛选,149 篇被纳入。社论和综述的参考文献中还包括了 189 条引文,因此共有 338 篇总出版物。常见报告的症状和并发症包括呼吸困难、咳嗽、喘息、咳痰、咯血和加重。与一般人群相比,报告了几种指数的疾病严重程度和增加的死亡率。支气管扩张症对几项患者报告的结局的生活质量产生了影响,患者经历疲劳、焦虑和抑郁。医疗资源利用量相当大,与住院、治疗以及急诊和门诊就诊相关的大量医疗费用被累积。间接成本包括病假和收入损失。
支气管扩张症会导致严重的临床和社会经济负担。需要使用能够减轻症状、改善生活质量以及减少医疗资源利用和总体成本的疾病修正治疗。对特定病因和儿科疾病的进一步系统分析可能会提供更多对未满足治疗需求的了解。